We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CytoSorbents Corporation Broadens its Intellectual Property Portfolio
Product News

CytoSorbents Corporation Broadens its Intellectual Property Portfolio

CytoSorbents Corporation Broadens its Intellectual Property Portfolio
Product News

CytoSorbents Corporation Broadens its Intellectual Property Portfolio


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "CytoSorbents Corporation Broadens its Intellectual Property Portfolio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CytoSorbents Corporation, a critical care focused company using blood purification to treat life-threatening illnesses, announced the issuance of two additional U.S. patents, bringing its total patent portfolio to 29 issued patents.

U.S. Patent 7,846,650 is titled "Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood" and covers a number of different hemocompatible device configurations to treat a variety of acute and chronic disorders including sepsis, trauma, myocardial ischemia and reperfusion injury, biologic or chemical warfare, renal disease, and others.

U.S. Patent 7,875,182 titled "Size-selective hemoperfusion polymeric adsorbents" describes the production of polymer beads ideally suited for the treatment of chronic diseases such as renal failure and auto-immune diseases.

Dr. Phillip Chan, Chief Executive Officer, stated, "These awarded patents add to an already substantial patent portfolio that broadly covers the use of our biocompatible porous polymer beads to treat a variety of conditions and diseases. We continue to invest significantly in research and development, expanding the potential applications of our purification technology, and increasing our pipeline of licensable products. Our long-term goal is to maximize the value of our technology and create lasting shareholder value."

Advertisement